Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
How do you approach pre-operative risk assessment and optimization in a patient with interstitial lung disease?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
What is your approach to bronchiolocentric interstitial pneumonia patterns observed on histology?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
Would you consider using steroids in patients with respiratory failure caused by aspiration pneumonitis?
Do you routinely integrate telomere length testing into the evaluation of patients with ILD?
